Johnson & Johnson News - July 2026
🟢 Johnson & Johnson is trading 3.1% up today after $5.5B talc settlement announcement
Johnson & Johnson is trading 3.1% up today at $273.75 after announcing a $5.5 billion agreement to resolve outstanding ovarian talc litigation, removing a...
JNJ Reaches $5.5 Billion Agreement to Resolve Ovarian Talc Litigation
Johnson & Johnson announced it has reached an agreement to resolve the outstanding ovarian talc litigation. The comprehensive resolution is designed to address...
Johnson & Johnson Myeloma Combo Cuts Progression Risk 89% in Phase 3
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study for multiple myeloma. The trial evaluated a dual-antigen regimen...
Judge Casts Doubt on Evidence in 69,000 J&J Talc Lawsuits
A U.S. federal judge has raised significant doubts about the scientific evidence underpinning approximately 69,000 lawsuits alleging Johnson & Johnson's talc...
Johnson & Johnson's second quarter 2026 revenue of $25.3B beats estimates as the company raises its full-year outlook.
Johnson & Johnson reported second quarter 2026 revenue of $25.31 billion, up 6.6% year-over-year, and adjusted EPS of $2.90, an increase of 4.7%. The results...
Johnson & Johnson Q2 2026 Earnings Preview: What Analysts Expect on July 15, 2026
For the second quarter of 2026, analysts expect Johnson & Johnson to report consensus revenue of $25.18 billion and adjusted EPS of $2.85, with the stock...
🟢 JNJ is trading 3.5% up today, driven by positive clinical trial results and a significant investment
• Shares are currently trading at $268.46, up 3.5%, rebounding sharply from the prior session’s decline. • Johnson & Johnson highlighted positive primary...